Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OKT3 + ANTAG2
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OKT3 + ANTAG2 is a **combination immunosuppressive therapy** consisting of OKT3 (muromonab-CD3), a murine monoclonal antibody that binds to the CD3 antigen on human T cells, and ANTAG2, for which no standard substance or published pharmacologic profile is currently identified. - **OKT3** (muromonab-CD3) functions as a potent immunosuppressant by binding to CD3 on T cells, rapidly depleting peripheral CD3+ lymphocytes, and modulating the CD3/T-cell receptor complex, thereby blocking T-cell activation and proliferation. This immunosuppression is exploited clinically to prevent and treat organ transplant rejection and has been tested in various autoimmune conditions[2][3][5][6][8]. - **ANTAG2** does not correspond to any widely recognized or described monoclonal antibody, immunosuppressive drug, or therapeutic agent in scientific references; its mechanism, target, and role are unknown, and so no mechanistic or regulatory data can be provided for this component of the combination. - The combination is presumably parenteral (IV), based on standard OKT3 use.
- Brand names
- Orthoclone OKT3
- Other names
- muromonab-CD3 + ANTAG2
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on OKT3 + ANTAG2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OKT3 + ANTAG2.